Telix Pharmaceuticals Ltd — Board/Management Information 2020

Mar 8, 2020

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [147 x 81] intentionally omitted <==

Leader in prostate cancer imaging Prof. Frederik L. Giesel joins Scientific Advisory Board

Melbourne (Australia) – 9[th] March 2020. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board (SAB). As a member of Telix’s SAB, Prof. Giesel will advise Telix in relation to its R&D and clinical development activities spanning the Company’s prostate cancer, kidney cancer and glioblastoma (brain cancer) programs.

Prof. Giesel, who is Vice Chair in the Department of Nuclear Medicine at the University of Heidelberg (Germany) is a leader in the field of cancer imaging and the use of positron emission tomography (PET) for the evaluation of prostate cancer. Prof. Giesel is currently the lead investigator on the German Cancer Research Centre’s multicentre study of PET imaging using[68] Ga-PSMA-11 in newly diagnosed prostate cancer patients at high risk for metastasis, a group commonly referred to as ‘high risk men’.[1]

Telix’s CEO Dr Chris Behrenbruch said “We are delighted to welcome Prof. Giesel onto Telix’s Scientific Advisory Board, where together with a group of highly accomplished colleagues, he will provide invaluable input into our efforts to improve the lives of patients living with prostate, kidney and brain cancers. Prof Giesel has been at the vanguard of the development of cancerspecific PET tracers and has been instrumental in the clinical introduction of PSMA-based imaging for men with prostate cancer.”

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telix.com.

Telix Corporate Contact

Telix Investor Relations

Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com

Dr David N. Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: david.cade@telixpharma.com

1 Clinicaltrials.gov Identifier: NCT03362359

Page 1

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

Page 2